These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6120666)

  • 21. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.
    Friedman J; Ault K; Powchik P
    Biol Psychiatry; 1997 Sep; 42(6):522-3. PubMed ID: 9285089
    [No Abstract]   [Full Text] [Related]  

  • 22. "Postpsychotic depression" and residual schizophrenia in a mental health hospital.
    Mauri MC; Laini V; Barone R; Clemente A; Volonteri LS; Cerveri G; Steinhilber C; Fornier M
    Encephale; 2000; 26(6):21-6. PubMed ID: 11217534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical and statistical evaluation of neuroleptic pimozide].
    Glatzel J
    Int Pharmacopsychiatry; 1971; 6(1):60-6. PubMed ID: 5163169
    [No Abstract]   [Full Text] [Related]  

  • 24. Childhood stressors, parental expectation, and the development of schizophrenia.
    Mirsky AF; Ingraham LJ; Lowing PA
    Prog Exp Pers Psychopathol Res; 1992; 15():110-30. PubMed ID: 1364178
    [No Abstract]   [Full Text] [Related]  

  • 25. A study of anxiolytic property of 'CIBA-GO3315 A', a new butyrophenone.
    Mehta NC; Khorana AB
    J Assoc Physicians India; 1982 Jul; 30(7):433-6. PubMed ID: 6132911
    [No Abstract]   [Full Text] [Related]  

  • 26. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 27. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
    Himelhoch S; Taylor SF; Goldman RS; Tandon R
    Biol Psychiatry; 1996 Feb; 39(3):227-9. PubMed ID: 8837987
    [No Abstract]   [Full Text] [Related]  

  • 28. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?
    Gaebel W; Frick U; Köpcke W; Linden M; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients.
    van Berckel BN; Hijman R; van der Linden JA; Westenberg HG; van Ree JM; Kahn RS
    Biol Psychiatry; 1996 Dec; 40(12):1298-300. PubMed ID: 8959296
    [No Abstract]   [Full Text] [Related]  

  • 30. [Weight gain and clozapine].
    Jalenques I; Tauveron I; Albuisson E; Audy V
    Encephale; 1996 Oct; 22 Spec No 3():77-9. PubMed ID: 8954282
    [No Abstract]   [Full Text] [Related]  

  • 31. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
    Wittorf A; Sickinger S; Wiedemann G; Klingberg S
    Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of different psychotropic drugs on psychotic anxiety.
    Nahunek K; Svestka J; Ceskova E
    Agressologie; 1981 Nov; 22(D):11-3. PubMed ID: 7332036
    [No Abstract]   [Full Text] [Related]  

  • 33. Seroquel and cognitive improvement in patients with schizophrenia.
    Stip E; Lussier I; Babai M; Fabian JL; Link C
    Biol Psychiatry; 1996 Sep; 40(5):434-5. PubMed ID: 8874852
    [No Abstract]   [Full Text] [Related]  

  • 34. [Early phase II study of quetiapine fumarate on schizophrenia].
    Murasaki M; Yamauchi T; Yagi G; Nakajima T; Nakane Y; Kudo Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Apr; 19(2):53-66. PubMed ID: 10464776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Violence and schizophrenia: clozapine as a specific antiaggressive agent.
    Buckley P; Bartell J; Donenwirth K; Lee S; Torigoe F; Schulz SC
    Bull Am Acad Psychiatry Law; 1995; 23(4):607-11. PubMed ID: 8639988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ICI 204,636: a new atypical antipsychotic drug.
    Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
    Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
    [No Abstract]   [Full Text] [Related]  

  • 38. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.
    Molero P; Ortuño F; Zalacain M; Patiño-García A
    Pharmacogenomics J; 2007 Dec; 7(6):418-26. PubMed ID: 17363961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AHR 6134--a new anxiolytic drug with unusual clinical properties.
    Benber HC; Feldmann H
    Prog Neuropsychopharmacol; 1978; 2(1):117-22. PubMed ID: 31643
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.